ストックスクリーナーアプリを入手
21.97
1.44%
-0.32
アフターアワーズ：
21.91
-0.06
-0.27%
前日終値:
$22.29
開ける：
$22.33
24時間の取引高:
210.92K
Relative Volume:
0.61
時価総額：
$906.95M
収益：
-
当期純損益:
$-136.98M
株価収益率:
-5.4652
EPS:
-4.02
ネットキャッシュフロー:
$-126.63M
1週間 パフォーマンス:
-0.18%
1か月 パフォーマンス:
-4.69%
6か月 パフォーマンス:
-3.68%
1年 パフォーマンス:
-20.34%
1日の値動き範囲:
$21.81
$22.81
1週間の範囲:
$21.81
$22.81
52週間の値動き範囲:
$15.47
$29.71
Arrivent Biopharma Inc Stock (AVBP) Company Profile
AVBP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
21.97 | 920.16M | 0 | -136.98M | -126.63M | -4.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.90 | 117.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.97 | 82.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.59 | 52.94B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
844.92 | 52.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.88 | 37.84B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-10 | 開始されました | BTIG Research | Buy |
| 2025-11-25 | 開始されました | Truist | Buy |
| 2025-07-10 | 再開されました | Goldman | Buy |
| 2025-03-20 | 開始されました | B. Riley Securities | Buy |
| 2025-03-10 | 開始されました | Guggenheim | Buy |
| 2024-07-22 | 開始されました | Oppenheimer | Outperform |
| 2024-04-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-02-20 | 開始されました | Citigroup | Buy |
| 2024-02-20 | 開始されました | Goldman | Buy |
| 2024-02-20 | 開始されました | Jefferies | Buy |
すべてを表示
Arrivent Biopharma Inc (AVBP) 最新ニュース
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts (NASDAQ:AVBP) - Seeking Alpha
(AVBP) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
ArriVent BioPharma (NASDAQ:AVBP) Trading Down 3.2%What's Next? - MarketBeat
ArriVent doses first patient in pivotal phase 3 trial for lung cancer drug - Investing.com Nigeria
ArriVent Biopharma initiated with an Overweight at Cantor Fitzgerald - TipRanks
Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating By Investing.com - Investing.com Canada
Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating - Investing.com
ArriVent Biopharma announces first patient dosed in Phase 3 ALPACCA study - TipRanks
ArriVent BioPharma Begins Phase 3 Trial of Firmonertinib in Lung Cancer - marketscreener.com
ArriVent BioPharma Initiates Pivotal Phase 3 ALPACCA Study of Firmonertinib for First-Line Treatment of EGFR PACC Mutant NSCLC - Quiver Quantitative
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer - marketscreener.com
New lung cancer trial tests a daily chemo-free pill for rare mutation - Stock Titan
Investment Recap: Will ArriVent BioPharma Inc. stock benefit from AI adoptionLong Setup & Daily Profit Maximizing Tips - Улправда
Will ArriVent BioPharma Inc. stock benefit from AI adoptionQuarterly Portfolio Review & Free AI Powered Buy and Sell Recommendations - Улправда
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Will ArriVent BioPharma Inc. stock pay special dividendsTrade Volume Summary & Low Drawdown Investment Strategies - ulpravda.ru
Will ArriVent BioPharma Inc. stock remain a Wall Street favorite2025 Technical Overview & Real-Time Buy Zone Alerts - Улправда
Why ArriVent BioPharma Inc. stock is recommended by analystsMarket Trend Summary & Weekly Breakout Watchlists - Улправда
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 5.6%Here's What Happened - MarketBeat
Will ArriVent BioPharma Inc. stock deliver consistent dividendsJuly 2025 Price Swings & AI Forecasted Entry and Exit Points - Улправда
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B (2025-12-16) - Seeking Alpha
Squarepoint Ops LLC Grows Stock Position in ArriVent BioPharma, Inc. $AVBP - MarketBeat
ArriVent BioPharma Earnings Notes - Trefis
ArriVent Biopharma initiated with a Buy at BTIG on firmonertinib potential - MSN
Fund 1 Investments LLC Acquires New Position in ArriVent BioPharma, Inc. $AVBP - MarketBeat
Why (AVBP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
BTIG Research Begins Coverage on ArriVent BioPharma (NASDAQ:AVBP) - Defense World
ArriVent BioPharma Inc (AVBP) is looking forward to a strong quarter - setenews.com
ArriVent BioPharma (NASDAQ:AVBP) Coverage Initiated at BTIG Research - MarketBeat
BTIG initiates coverage of ArriVent BioPharma (AVBP) with buy recommendation - MSN
ArriVent BioPharma stock initiated with Buy rating at BTIG on oncology potential - Investing.com Canada
ArriVent Biopharma initiated with a Buy at BTIG - TipRanks
BTIG Initiates ArriVent BioPharma at Buy With $45 Price Target - marketscreener.com
ArriVent BioPharma (NASDAQ:AVBP) versus Sunshine Biopharma (NASDAQ:SBFM) Critical Review - Defense World
Buy Rating for ArriVent BioPharma, Inc. Driven by Promising Developments in EGFR Exon 20 NSCLC Treatment - TipRanks
Is ArriVent BioPharma Inc (AVBP) positioned for future growth? - Setenews
Buy Rating for ArriVent BioPharma Driven by Promising Firmonertinib Trial Results - TipRanks
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 6.4%Here's What Happened - MarketBeat
Understanding Momentum Shifts in (AVBP) - Stock Traders Daily
ArriVent BioPharma Taps Brent S. Rice as Chief Commercial Officer - MSN
How ArriVent BioPharma Inc. stock trades before earnings2025 Trading Volume Trends & Accurate Trade Setup Notifications - Newser
Will ArriVent BioPharma Inc. stock sustain high P E ratiosWeekly Market Outlook & Stepwise Trade Signal Implementation - Newser
A new trading data show ArriVent BioPharma Inc (AVBP) is showing positive returns. - Setenews
ArriVent BioPharma (NASDAQ:AVBP) Coverage Initiated at Truist Financial - MarketBeat
Truist Financial Initiates Coverage on ArriVent BioPharma (NASDAQ:AVBP) - Defense World
ArriVent Biopharma initiated with a Buy at Truist - TipRanks
ArriVent BioPharma stock initiated with Buy rating at Truist on lung cancer drug - Investing.com Canada
Truist Initiates ArriVent BioPharma at Buy With $43 Price Target - marketscreener.com
AXQ Capital LP Buys New Position in Intellia Therapeutics, Inc. $NTLA - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Arrivent Biopharma Inc (AVBP) 財務データ
収益
当期純利益
現金流量
EPS
0.08%
0.21%
大文字化:
|
ボリューム (24 時間):